Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMA950 and Poly-ICLC with Temozolomide in Newly Diagnosed Glioblastoma
NCT01920191Phase 2Completed
- Start
- Aug 2013
- Primary completion
- Mar 2016
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of IMA950 in glioblastoma (GBM). Started Aug 2013; status: completed.
02
Drugs
IMA950
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT01920191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01920191.